Candesartan as a tentative treatment for COVID-19: A prospective non-randomized open-label study
Background: This study aimed to investigate whether the addition of candesartan to the standard care regimen improved the outcome in patients with coronavirus 2019 (COVID-19). Methods: A prospective non-randomized open-label study was undertaken from May to August 2020 on 75 subjects (aged 18–70 years) hospitalized in Siloam Kelapa Dua Hospital. Uni- and multi-variable Cox regression analyses were performed to obtain hazard ratios (HRs). The primary outcomes were: (1) length of hospital stay; (2) time to negative swab; and (3) radiological outcome (time to improvement on chest X ray). Results: None of the 75 patients with COVID-19 required intensive care. All patients were angiotensin-receptor-blocker naïve. In comparison with the control group, the candesartan group had a significantly shorter hospital stay [adjusted HR 2.47, 95% confidence interval (CI) 1.16–5.29] after adjusting for a wide range of confounders, and no increased risk of intensive care. In the non-obese subgroup, the candesartan group had a shorter time to negative swab (unadjusted HR 2.11, 95% CI 1.02–4.36; adjusted HR 2.40, 95% CI 1.08–5.09) and shorter time to improvement in chest x ray (adjusted HR 2.82, 95% CI 1.13–7.03) compared with the control group. Conclusion: Candesartan significantly reduces the length of hospital stay after adjustment for covariates. All primary outcomes improved significantly in the non-obese subgroup receiving candesartan..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:108 |
|---|---|
| Enthalten in: |
International Journal of Infectious Diseases - 108(2021), Seite 159-166 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Antonia Anna Lukito [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Angiotensin |
|---|
| doi: |
10.1016/j.ijid.2021.05.019 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ002455358 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ002455358 | ||
| 003 | DE-627 | ||
| 005 | 20230309170635.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2021.05.019 |2 doi | |
| 035 | |a (DE-627)DOAJ002455358 | ||
| 035 | |a (DE-599)DOAJ2d0466a438c342349a81974bb3a8f851 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC109-216 | |
| 100 | 0 | |a Antonia Anna Lukito |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Candesartan as a tentative treatment for COVID-19: A prospective non-randomized open-label study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background: This study aimed to investigate whether the addition of candesartan to the standard care regimen improved the outcome in patients with coronavirus 2019 (COVID-19). Methods: A prospective non-randomized open-label study was undertaken from May to August 2020 on 75 subjects (aged 18–70 years) hospitalized in Siloam Kelapa Dua Hospital. Uni- and multi-variable Cox regression analyses were performed to obtain hazard ratios (HRs). The primary outcomes were: (1) length of hospital stay; (2) time to negative swab; and (3) radiological outcome (time to improvement on chest X ray). Results: None of the 75 patients with COVID-19 required intensive care. All patients were angiotensin-receptor-blocker naïve. In comparison with the control group, the candesartan group had a significantly shorter hospital stay [adjusted HR 2.47, 95% confidence interval (CI) 1.16–5.29] after adjusting for a wide range of confounders, and no increased risk of intensive care. In the non-obese subgroup, the candesartan group had a shorter time to negative swab (unadjusted HR 2.11, 95% CI 1.02–4.36; adjusted HR 2.40, 95% CI 1.08–5.09) and shorter time to improvement in chest x ray (adjusted HR 2.82, 95% CI 1.13–7.03) compared with the control group. Conclusion: Candesartan significantly reduces the length of hospital stay after adjustment for covariates. All primary outcomes improved significantly in the non-obese subgroup receiving candesartan. | ||
| 650 | 4 | |a Angiotensin | |
| 650 | 4 | |a Candesartan | |
| 650 | 4 | |a Coronavirus | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Severity | |
| 653 | 0 | |a Infectious and parasitic diseases | |
| 700 | 0 | |a Allen Widysanto |e verfasserin |4 aut | |
| 700 | 0 | |a Theo Audi Yanto Lemuel |e verfasserin |4 aut | |
| 700 | 0 | |a Ignatius Bima Prasetya |e verfasserin |4 aut | |
| 700 | 0 | |a Billy Massie |e verfasserin |4 aut | |
| 700 | 0 | |a Mira Yuniarti |e verfasserin |4 aut | |
| 700 | 0 | |a Nicolaski Lumbuun |e verfasserin |4 aut | |
| 700 | 0 | |a Raymond Pranata |e verfasserin |4 aut | |
| 700 | 0 | |a Cindy Meidy |e verfasserin |4 aut | |
| 700 | 0 | |a Eka Julianta Wahjoepramono |e verfasserin |4 aut | |
| 700 | 0 | |a Irawan Yusuf |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t International Journal of Infectious Diseases |d Elsevier, 2015 |g 108(2021), Seite 159-166 |w (DE-627)DOAJ000043923 |x 18783511 |7 nnns |
| 773 | 1 | 8 | |g volume:108 |g year:2021 |g pages:159-166 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ijid.2021.05.019 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/2d0466a438c342349a81974bb3a8f851 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1201971221004203 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1201-9712 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 108 |j 2021 |h 159-166 | ||